finance.yahoo.com (nprofile…mr8r)
https://s.yimg.com/ny/api/res/1.2/hHgz.KvXyWSeOvY5iTG.7g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MzM-/https://media.zenfs.com/en/motleyfool.com/55917c323746a1ac555e10c5bfcba981
https://finance.yahoo.com/news/why-summit-therapeutics-rocketed-double-200500961.html
finance.yahoo.com / Yahoo! Finance
npub1va…rwc3n
2025-04-25 07:41:29
Author Public Key
npub1vap2usgr7nawhqexfk247ap0nfs34jqpjrxqqslrkv3rrrx8aessgrwc3nPublished at
2025-04-25 07:41:29Event JSON
{
"id": "dd24df2ee7af2329c2cb86ac0bc2e5c36eae4bef2197d26f010089a46313a9ff",
"pubkey": "6742ae4103f4faeb83264d955f742f9a611ac80190cc0043e3b322318cc7ee61",
"created_at": 1745566889,
"kind": 1,
"tags": [
[
"r",
"https://finance.yahoo.com/news/why-summit-therapeutics-rocketed-double-200500961.html"
],
[
"subject",
"Why Summit Therapeutics Rocketed Double-Digits Today"
],
[
"published_at",
"1745438700"
],
[
"image",
"https://s.yimg.com/ny/api/res/1.2/hHgz.KvXyWSeOvY5iTG.7g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MzM-/https://media.zenfs.com/en/motleyfool.com/55917c323746a1ac555e10c5bfcba981"
],
[
"p",
"6742ae4103f4faeb83264d955f742f9a611ac80190cc0043e3b322318cc7ee61",
"wss://articles.layer3.news"
],
[
"imeta",
"url https://s.yimg.com/ny/api/res/1.2/hHgz.KvXyWSeOvY5iTG.7g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MzM-/https://media.zenfs.com/en/motleyfool.com/55917c323746a1ac555e10c5bfcba981"
],
[
"t",
"mainstream:perspective"
],
[
"summary",
"The trial showed that ivonescimab delivered a statistically significant improvement in patients with locally advanced or metastatic squamous non-small cell lung cancer (NSCLC) compared to the current standard of care, tislelizumab. This news is significant as it could potentially lead to ivonescimab becoming a blockbuster drug, displacing existing standards of care."
]
],
"content": "nostr:nprofile1qyd8wumn8ghj7ctjw35kxmr9wvhxcctev4erxtnwv4mhxqpqvap2usgr7nawhqexfk247ap0nfs34jqpjrxqqslrkv3rrrx8aesst3mr8r\nhttps://s.yimg.com/ny/api/res/1.2/hHgz.KvXyWSeOvY5iTG.7g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MzM-/https://media.zenfs.com/en/motleyfool.com/55917c323746a1ac555e10c5bfcba981\n\nhttps://finance.yahoo.com/news/why-summit-therapeutics-rocketed-double-200500961.html",
"sig": "0f847c77a465ff6cc63e3634b9f51964e9c74628ccf1a4b07d5a0d9b61f9d2196e990be72d59a59889004853d5da5f1e1e95a6afbcfda1a82c29f2e3a3c89343"
}